June 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:
BIOMARIN PRESENTS FIVE-YEAR PHASE 3 RESULTS REINFORCING LONG-TERM EFFICACY AND SAFETY OF ROCTAVIAN® (VALOCTOCOGENE ROXAPARVOVEC-RVOX) AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS 2025 CONGRESS
BIOMARIN PHARMACEUTICAL INC - NO NEW SAFETY SIGNALS OBSERVED IN 5-YEAR ROCTAVIAN STUDY
Source text: ID:nPn9r74zka
Further company coverage: BMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.